Depomed Inc

Depomed — Assertio Therapeutics — Investor Presentation (January 2019)

20 slides from Depomed's investor presentation, Jan 7, 2019

  1. Slide 1: About this Presentation

    About this Presentation The statements that are not historical facts contained in this presentation are forward-looking statements including, but not limited to, statements relating to the commercialization of Gralise, CAMBIA, and Zipsor, royalties associated with Collegium’s commercialization of NU

  2. Slide 2: The "Old" Depomed: Primarily an Opioid-Based Company Prior to 2018

    Past 3 The “Old” Depomed Primarily an Opioid-Based Company Prior to 2018 NUCYNTA and Lazanda franchises place Depomed with a heavy opioid concentration in a volatile market NUCYNTA 300 person field force needed to be downsized and retargeted with significant dislocation risk Promotionally-sensitive

  3. Slide 3: Transformation Underway to Leaner, Faster-Moving, More Entrepreneurial Company

    4 Transformation Underway to Leaner, Faster-Moving, More Entrepreneurial Company TRANSFORMATION: Exit Opioid Commercialization 2016 2018E # of Employees(1) ~500 ~120 Non-GAAP SG&A(2) $189 million $105 million(3) 2016 2017 2018 (1) Includes sales force. (2) Refer to Appendix for a reconciliation of a

  4. Slide 4: New Name, Renewed Mission: Advance Patient Care in Neurology, Orphan & Specialty

    New Name, Renewed Mission: Advance Patient Care in the Company’s Core Areas of Neurology, Orphan & Specialty Medicines 5 Assertio Therapeutics, Inc. (Assertio) is a new name that reflects a new business strategy, mission, vision and values A Company committed to putting patients first and creating s

  5. Slide 5: A Clear Strategy for Growth

    A Clear Strategy for Growth 6 Continued Execution of Three-Pillar Growth Strategy to Transform Company MAINTAIN a Strong/Profitable NUCYNTA® Franchise GROW Neurology Business BUILD a New Orphan/Specialty Business Amended and Strengthened Commercialization agreement with Collegium Pharmaceutical Stre

  6. Slide 6: Collegium Partnership Supports Maintaining a Strong/Profitable NUCYNTA Franchise

    Collegium Partnership Supports Maintaining a Strong/Profitable NUCYNTA® Franchise 7 MAINTAIN Original Contract As Amended $MM 4yrs; No Termination 2yrs; Term notice 1/1/19 4yrs Collegium Royalty Income $540 $270 $498.6(1) Upfront/Term Payment 10 35 10 Grünenthal Make Whole (18.4) (9.2) (4.6) Asserti

  7. Slide 7: Growing our Neurology Business

    Growing our Neurology Business A Portfolio with Extended Patent Exclusivity *Amended existing license agreement for a new presentation of Cambia which, if approved by FDA, may provide patent protection through at least 2026 ASSERTIO LAUNCH Q4 2011 Q2 2012 Q1 2014 INDICATIONS Management of postherpet

  8. Slide 8: Growing Our Neurology Business

    Growing Our Neurology Business 9 GROW Q3 ’18 stabilized core neurology brands with positive sequential total prescription growth for the franchise; but more work to do with Gralise® Q3 ’18 neurology product net sales increased $29.4 million, up 14 percent sequentially Q3 ‘18 began roll-out of new co

  9. Slide 9: Building a Specialty / Orphan Business

    Building a Specialty / Orphan Business Cosyntropin (synthetic ACTH depot) is First in a Portfolio of High-Value, High-Touch Orphan/Specialty Medicine Positioned to Address the Needs of Patients, Physicians and Payors 10 BUILD Filed for FDA approval of cosyntropin depot in Dec. 2018 1st Indication (d

  10. Slide 10: Improving Capital Structure

    Improving Capital Structure Current Secured Debt Payment Schedule Significantly De-levers Company 11 (1) Assumes mid-point of trailing 12-month adjusted EBITDA of $125 to $135; excludes PDL. $97 million in non-dilutive cash secured through transactions in 2018 combined with future operating cash flo

  11. Slide 11: Milestones Achieved in 2018

    Milestones Achieved in 2018 12 Synthetic cosyntropin (synthetic ACTH depot): Filed NDA in Dec. 2018 Amends and strengthens terms of Collegium Commercialization Agreement: Annual royalty payments secured through 2021 Agreement with PDL BioPharma to monetize royalty stream: Company received $20 millio

  12. Slide 12: Third-Quarter 2018 Five Key Messages

    13 Third-Quarter 2018 Five Key Messages 1. 2. 3. 4. 5. - Delivered a solid quarter - Continue to make excellent progress executing against 3-pillar strategy of Maintain, Grow & Build - Reaffirmed full-year guidance - Amended and strengthened Collegium agreement; eliminates any concern regarding earl

  13. Slide 13: Full-Year 2018 Financial Guidance

    Full-Year 2018 Financial Guidance 14 Prior 2018 Guidance Current 2018 Guidance Neurology Franchise Net Sales $105 to $110 million $105 to $110 million GAAP SG&A Expense $118 to $128 million $118 to $128 million GAAP R&D Expense $9 to $14 million $9 to $14 million Non-GAAP SG&A Expense $100 to $110 m

  14. Slide 14: Full-Year 2018 Financial Guidance

    Full-Year 2018 Financial Guidance Prior 2018 Guidance Current 2018 Guidance Neurology Franchise Net Sales $105 to $110 million $105 to $110 million GAAP SG&A Expense $118 to $128 million $118 to $128 million GAAP R&D Expense $9 to $14 million $9 to $14 million Non-GAAP SG&A Expense $100 to $110 mill

  15. Slide 15: Note Regarding Use of GAAP and Non-GAAP Financial Measures

    16 Note Regarding Use of GAAP and Non-GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company’s financial results presented on a U.S. generally accepted accounting principles (GAAP) basis, the Company has included information about non-GAAP revenue, non-GAAP adjusted earnings,

  16. Slide 16: Non-GAAP Reconciliation

    17 Non-GAAP Reconciliation (in millions) (unaudited)

  17. Slide 17: Non-GAAP Reconciliation

    18 Non-GAAP Reconciliation (in millions) (unaudited)

  18. Slide 18: Full-Year 2018 Non-GAAP Guidance Reconciliation

    19 Full-Year 2018 Non-GAAP Guidance Reconciliation (in millions) (unaudited)

  19. Slide 19: Full-Year 2018 Non-GAAP Guidance Reconciliation

    Full-Year 2018 Non-GAAP Guidance Reconciliation (in millions) (unaudited) FULL-YEAR 2018 NON-GAAP GUIDANCE RECONCILATION Specified Items” So oMSS ous $ (1) GAAP net income guidance refers to GAAP net income and non-GAAP eamings guidance refers to non-GAAP adjusted (@) Fer purposes ofthis forward-loo

  20. Slide 20: Assertio Therapeutics, January 2019

    /SSSSERTIO= January 2019

Assertio Therapeutics — Investor Presentation (January 2019) on 6ix